UroShield for preventing catheter-associated urinary tract infections (MTG69)Product type:GuidanceProgramme:Medical technologies guidancePublished: 31 March 2022
ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections (MTG62)Product type:GuidanceProgramme:Medical technologies guidancePublished: 13 December 2021
Clostridioides difficile infection: antimicrobial prescribing (NG199)Product type:GuidanceProgramme:NICE guidelinePublished: 23 July 2021
Plus Sutures for preventing surgical site infection (MTG59)Product type:GuidanceProgramme:Medical technologies guidancePublished: 28 June 2021
Leukomed Sorbact for preventing surgical site infection (MTG55)Product type:GuidanceProgramme:Medical technologies guidancePublished: 3 February 2021
Surgical site infections: prevention and treatment (NG125)Product type:GuidanceProgramme:NICE guidelineLast updated: 19 August 2020Published: 11 April 2019
Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues (IPG666)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 January 2020
Tegaderm CHG securement dressing for vascular access sites in critically ill adults (MTG25)Product type:GuidanceProgramme:Medical technologies guidanceLast updated: 18 September 2019Published: 22 July 2015
Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)Product type:GuidanceProgramme:NICE guidelinePublished: 16 September 2019
Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 July 2019
Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)Product type:GuidanceProgramme:NICE guidelinePublished: 23 November 2018
Healthcare-associated infections: prevention and control in primary and community care (CG139)Product type:GuidanceProgramme:Clinical guidelineLast updated: 15 February 2017Published: 28 March 2012
Faecal microbiota transplant for recurrent Clostridium difficile infection (IPG485)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 March 2014
Healthcare-associated infections: prevention and control (PH36)Product type:GuidanceProgramme:Public health guidelinePublished: 11 November 2011
GID-MT566 Faecal microbiota transplant for recurrent Clostridioides difficile infectionStatus:In developmentProgramme:Medical technologies guidanceExpected publication date: 30 August 2022
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 4 January 2023
Clostridium difficile associated diarrhoea - tolevamer [ID378]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus [ID1203]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC